Lupin Reports Record Q1 FY27 with ₹8,277 Cr Revenue, EBITDA ₹2,464 Cr
Lupin reported record Q1 FY27 results with revenue at ₹8,277 Cr and EBITDA at ₹2,464 Cr, a 32% and 50% YoY increase respectively. U.S. sales reached USD 366 million. India business grew 13.9% YoY. The company reaffirmed full-year guidance of high single-digit revenue growth and 25% EBITDA margins.
The announcement details record financial performance, significant growth in key markets, and provides a clear outlook for the fiscal year, which are material factors for investors.
The company reported record revenues and EBITDA, along with strong YoY growth across multiple geographies, exceeding expectations and reaffirming positive future guidance.
Lupin Limited announced a record first quarter for FY2027, with total revenues from operations reaching ₹8,277 crores and EBITDA at ₹2,464 crores, marking the 16th consecutive quarter of year-on-year growth. The company achieved over 20% YoY growth in ex-U.S. organic revenue, with strong double-digit growth across key markets including India, Other Developed Markets, and Other Emerging Markets.
The U.S. business posted sales of USD 366 million, a 30% YoY increase in constant currency, driven by higher volumes in the base portfolio, though partially offset by increased competition in products like Mirabegron. For the full year, the U.S. business is projected to be in the USD 1.1 billion to USD 1.2 billion range, with a focus on doubling the share of complex products, including respiratory and complex injectables, and augmented by biosimilars. The company plans to launch over 50 products in the U.S. in the next three years, including 10 exclusive first-to-files and five biosimilars.
India's business grew by 13.9% YoY to ₹2,380 crores, with the core prescription business growing 15.1% YoY, outperforming the IPM growth. The Diabetes segment showed robust growth at 31.8% YoY. Lupin aims for novel proprietary products to contribute one-third of its India revenues within 10 years.
Other Developed Markets, including Europe, Canada, and Australia, accounted for 14% of revenues and grew by 48% YoY, with European business showing 83% growth. Emerging markets delivered an impressive 52% YoY growth, led by Brazil, South Africa, and the Philippines.
Research and Development (R&D) spend was 7.4% of sales, focusing on complex and specialty platforms. The company received Establishment Inspection Reports (EIRs) with Voluntary Action Indicated (VAI) status from the U.S. FDA for its Ankleshwar and Somerset sites.
Lupin reiterates its full-year guidance of high single-digit revenue growth and EBITDA margins of around 25%. The company anticipates some moderation in performance in the remainder of the year due to increased competition in the U.S. market.
What to do with a filing like this
Lupin Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lupin Limited. Read the original for the full detail.